期刊文献+

冠心病患者阿司匹林抵抗的初步观察

Aspirin Resistance in Coronary Heart Disease Patients.
下载PDF
导出
摘要 目的初步探讨冠心病患者的阿司匹林抵抗(AR)现象及其相关因素。方法经冠脉造影确诊为冠心病患者156例,服用阿司匹林100mg/d≥1周后,分别用花生四烯酸(AA)、二磷酸腺苷(ADP)作诱导剂检测血小板聚集率(PAG)。AA诱导的PAG≥20%,同时ADP诱导的PAG≥70%者为AR;仅符合其中一项为阿司匹林半抵抗(ASR);均不符合者为阿司匹林敏感(AS)。结果156例患者中AR发生率为22.44%(35例),ASR发生率是17.95%(28例),AS发生率是59.62%(93例)。AR+ASR组中的糖尿病患者所占比例(28.57%)较AS组(9.68%)多(P<0.05);AR+ASR组患者血浆总胆固醇、低密度脂蛋白-胆固醇浓度显著高于AS组(P<0.05)。结论服用小剂量阿司匹林的冠心病患者AR+ASR发生率为40.38%;AR或ASR者血浆胆固醇浓度较高;糖尿病患者AR或ASR发生率较高。 Objective To investigate the phenomenon and influence factors of aspirin resistance(AR) in coronary heart disease (CHD) patients. Methods One hundred and fifty six patients with angiographically documented CHD took aspirin 100 mg/d for ≥7 days, and then their blood samples were collected for detemfinafion of optical platelet aggregation (PAG) using arachidonic acid (AA) and adenosine diphosphate(ADP) as inducer. AR was defined as a state in which PAG ≥120% with AA as inducer and PAG ≥70% with ADP as inducer. Aspirin semiresistance (ASR) was defined as meeting one of above two criteria. The condition was defined as aspirin sensitive(AS), when both above criteria were not met. Results Of 156 CHD patients, 35 cases were AR (22.44%), 28 cases were ASR (17.95%), 93 cases were AS (59.62%). There were more diabetic patients in AR + ASR group titan in AS group (28.57% vs 9.68%, P 〈 0.005). The plasma level of total cholesterol and LDL-C(mmol/L) in AR+ ASR group was significandy higher titan that in AS group (5.00 ± 1.26 vs 4.54 ± 0.91, P 〈 0.05, 2.99 ± 0.95 vs 2.67 ± 0.64, P 〈 0.05, respectively). Conclusion The incidence of AR + ASR among CHD patients was 40.38%. The plasma level of total cholesterol and LDL-C in AR + ASR group was higher than that in AS group. The incidence of AR + ASR in diabetes meUitus patients was increased.
出处 《心脑血管病防治》 2007年第6期367-369,共3页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
基金 温州市科技局计划项目Y2005B027
关键词 冠心病 阿司匹林抵抗 血小板聚集率 Coronary heart disease Aspirin resistance Platelet aggregation
  • 相关文献

参考文献13

  • 1Simon S, Jon E, Trevor B, Ann-Louise K. Narrative review: Aspirin resis tance and its clinical implications[J]. Annals Inter Med, 2005,142(5) : 370 - 380.
  • 2Tran HA,Anand SS,Hankey GJ,et al. Aspirin resistance[J]. Thrombosis Research, 2007,120(3) :337 - 346.
  • 3Gum PA, Kottke-Marchant K, Poggio ED. Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J]. Am J Cardiol, 2001,88 (3) :230 - 235.
  • 4Bhatt DL, Topol EJ. Scientific and therapeutic advances inantiplatelet ther apy[J]. Nature Rev Drug Discov, 2003, 2(1): 15-28.
  • 5Valles J, Santos M, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity [J]. Circulation, 1998, 97: 350- 355.
  • 6Patrono C. Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage[J]? Thromb IRes, 1998, 92:s7 - s12.
  • 7Marc K, Perry V. Why are some individuals resistant to the cardioprotective effects of aspirin? Coud it be thromboxame A2[J]. Circulation, 2002, 105 (4) : 1650- 1622.
  • 8John W, Jack H, Jeffrey I, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke,or cardiovascular death in patients at high risk for cardiovascular events[J]. Circulation, 2002, 105 (4) : 1620 - 1655.
  • 9Angiolillo DJ, Fernandez-Ortiz A, Bemardo E, et al. Influence of aspirin resistance on platelet fimction profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention [ J ]. Am J Cardiol, 2006, 97(1): 38-43.
  • 10Hobikoglu GF, NorsazT, Aksu H, et al. High frequency of aspirin resistance in patients with acute coronary syndrome [ J ]. Tohoku J Exp Med, 2005, 207(1): 59-64.

二级参考文献20

  • 1Anonymous.Collaborative overview of randomized trials of antiplatelet therapy-Ⅰ-Ⅲ[J].BMJ,1994,308(6921-6923):81106,159-168,235-246.
  • 2Helgason C M,Bolin K M,Hoff J A,et al.Development of aspirin resistance in persons with previous ischemic stroke[J].Stroke,1994,25:2331-2336.
  • 3Pappas J M,Westengard J C,Bull B S.Population variability in the effect of aspirin on platelet function:implication for clinical trials and therapy[J].Arch Pathol Lab Med,1994,118:801-804.
  • 4Grotemeyer K H,Scharafinski H W,Husstedt I W.Two-year follow-up of aspirin responder and aspirin non-responder:a pilot-study including 180 post-stroke patients[J].Thromb Res,1993,71:397-403.
  • 5Gum P A,Kotike-Marchant K,Poggio E D,et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J].Am J Cardiol,2001,88:230-235.
  • 6Gum P A,Kottke-Marchant K,Welsh P A,et al.A Prospective,blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease[J].J Am Coll Cardiol,2003,41:961-965.
  • 7Lee P Y,Chen W H,Ng W,et al.Low-dose aspirin increases aspirin resistance in patients with coronary artery disease[J].Am J Med,2005,118:723-727.
  • 8Valles J,Santos M T,Aznar J,et al.Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality:the effect of low-does is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity[J].Circulation,1998,97:350-355.
  • 9Patrono C.Prevention of myocardial infarction and stroke by aspirin:different mechanisms? Different dosage[J]?Thromb Res,1998,92:s7s12.
  • 10Taylor D W,Barnett H J,Haynes R B,et al.Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy:a randomized controlled trial.ASA and Carotid Endarterectomy(ACE) trial collaborators[J].Lancet,1999,353:2179-2184.

共引文献33

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部